Prognostic factors for efficacy of Ipilimumab used after anti-PD1 and/or BRAF+MEK inhibitors in melanoma patients: An Italian melanoma intergroup study

The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy

“…Eleven studies were excluded due to no relevant outcomes (n=8), review and meta-analyses (n=2), and duplicates (n=1). Finally, 18 studies including 2054 patients were included in the meta-analysis 27–31,38–50…”

“…Inflammation-induced cancer dedifferentiation has been reported to be highly associated with the acquired resistance to cancer immunotherapy 57. Increasing studies have reported the prognostic value of baseline NLR in melanoma patients receiving immunotherapy 28,29,46,47. However, a comprehensive analysis is lacking and stronger evidence is needed to highlight the association between baseline NLR and the prognosis of melanoma patients receiving immunotherapy.…”

“…Finally, 18 studies including 2054 patients were included in the meta-analysis. [27][28][29][30][31][38][39][40][41][42][43][44][45][46][47][48][49][50] The main characteristics of the included studies were summarized in Table 1. All the studies were published between 2015 and 2020, with 5 studies published before 2018.…”